Medical Oncology · Acibadem Atasehir Hospital, İstanbul Prof. Özge Gümüşay, MD
✓ Medically verified profileProf. Özge Gümüşay, MD
Prof. Özge Gümüşay, MD is a medical oncologist in the Medical Oncology Department at Acibadem Atasehir Hospital in İstanbul, Turkey, with more than 21 years in medicine. Her clinical interests are breast cancer and male breast cancer. She consults in Turkish and English, and video consultation is available for international patients.
Accepting international patientsAbout Prof. Özge Gümüşay, MD
Prof. Özge Gümüşay, MD is a medical oncologist at Acibadem Atasehir Hospital in İstanbul, where she works in the Medical Oncology Department. Her clinical interests are breast cancer and male breast cancer. With more than 21 years in medicine, she provides oncology care with a focus on clear communication and individualised treatment planning.
Dr. Gümüşay graduated from Hacettepe University Faculty of Medicine in 2005. She completed her Internal Medicine training at Gazi University Faculty of Medicine in 2010 and her Medical Oncology training at the same faculty in 2014, having worked there as a research assistant in both disciplines from 2006 to 2014. From 2014 to 2019 she was a Medical Oncology Specialist at Gaziosmanpaşa University Faculty of Medicine, where she became an Associate Professor in 2017. Between 2019 and 2021 she gained breast cancer oncology experience at UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, and in 2021 she worked at Stanford University Comprehensive Cancer Center in Palo Alto, California. In 2023 she became a Professor at Acıbadem University Faculty of Medicine. She is a member of the American Society of Clinical Oncology (ASCO), The European Society of Medical Oncology (ESMO) and the Turkish Medical Oncology Association (TTOD). Her publications include work on CDK4/6 inhibitor resistance in breast cancer, immunotherapy in triple-negative breast cancer, the identification and management of immunotherapy toxicity, liquid biopsy, and percutaneous vertebral augmentation in patients with metastatic breast cancer.
Clinical focus
Dr. Gümüşay’s clinical work centres on breast cancer treatment from a medical oncology perspective. This involves reviewing each patient’s pathology, imaging and previous treatments, considering the individual characteristics of the disease, and discussing the medical oncology options that may be appropriate. Her published research on resistance to targeted therapies and on immunotherapy in breast cancer reflects the areas she follows closely in her clinical practice.
She also has a clinical interest in male breast cancer. Men diagnosed with breast cancer can consult her for assessment of their reports and imaging and for a discussion of the medical oncology options relevant to their situation.
How Dr. Gümüşay works with international patients
Dr. Gümüşay consults in Turkish and English, and interpreters can be arranged for patients who speak other languages. Before a visit, the Acibadem international patient team coordinates the collection of prior reports and imaging, such as MRI, CT, X-ray or ultrasound reports, laboratory and pathology results, operative notes and discharge summaries, arranges appointments and organises the hospital visit. A first consultation typically covers the patient’s history and symptoms, a review of existing imaging and previous treatments, a clinical examination and a discussion of the options. Video consultation is available for international patients who wish to discuss their case with Dr. Gümüşay before travelling or as part of a case review.
What Dr. Gümüşay treats and performs
Each item opens the condition or treatment page with the care pathway for international patients.
Conditions treated
Procedures performed
Education, career and memberships
Education & training
Education
- 2023Acıbadem University Faculty of Medicine / Professor
- 2021Stanford University Comprehensive Cancer Center, Palo Alto, California
- 2019–2021UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, (Breast Cancer Oncology)
- 2017Gaziosmanpaşa University Faculty of Medicine / Associate Professor
- 2014Gazi University Faculty of Medicine Medical Oncology
- 2010Gazi University Faculty of Medicine Internal Medicine
- 2005Hacettepe University Faculty of Medicine
Career
Professional Experience
- 2022Acıbadem Healthcare Services
- 2014–2019Gaziosmanpaşa University Faculty of Medicine, Medical Oncology Specialist
- 2010–2014Gazi University Faculty of Medicine, Medical Oncology Subspecialty Research Assistant
- 2006–2010Gazi University Faculty of Medicine, Internal Medicine Research Assistant
Memberships
Professional Memberships
- American Society of Clinical Oncology (ASCO)
- The European Society of Medical Oncology (ESMO)
- Turkish Medical Oncology Association (TTOD)
Selected publications
Selected Publications
- CDK4/6 inhibitors: Mechanisms of resistance and potential biomarkers of responsiveness in breast cancer Future Oncology, 2022 Mar;18(9):1143-1157. Cetin B, Wabl CA, Gumusay O.
- Immunotherapy Toxicity: identification and management Breast Cancer Res Treat 2022 Feb;192(1):1-17. Gumusay O, Callan J, Rugo HS.
- Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy. Front. Oncol., March 15, 2022. (share first authorship) Magbanua MJ, Gumusay O, Kurzrock R, vant Veer LJ, Rugo HS.
- The role of percutaneous vertebral augmentation in patients with metastatic breast cancer: Literature review including report of two cases Breast. 2022 Apr 2;63:149-156. Gumusay O, Huppert LA, Behr SC, Rugo HS.
- Emerging treatment strategies for metastatic triple-negative breast cancer. Therapeutic Advances in Medical Oncology. January 2022. Huppert LA, Gumusay O, Rugo HS.
- Trials of Immunotherapy in Triple Negative Breast Cancer. Curr Breast Cancer Rep 13, 171185 (2021). Gumusay O, Wabl, CA, Rugo HS.
- Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020 Jun 25;382(26): e108. Cetin B, Gumusay O.
- Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. Am Soc Clin Oncol Educ Book. 2020 May;40:e292-e308. Gumusay O, Vitiello PP, Wabl C, Corcoran RB, Bardelli A, Rugo HS.
- Factors Influencing Chemotherapy Goal Perception in Newly Diagnosed Cancer Patients J Cancer Educ. 2016 Jun;31(2):308-13. Gumusay O, Cetin B, Benekli M, Gurcan G, Ilhan MN, Bostankolu B, Ozet A, Uner A, Coskun U, Buyukberber S.
- Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites Japanese Journal of Clinical Oncology. 2015 May; 45(5), 416-421. Gumusay O, Benekli M, Ekinci O, Baykara M, Ozet A, Coskun U, Demirci U, Uner A, Dursun A, Atak EY, Buyukberber S.
